Stock ELOX ELOXX PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Eloxx Pharmaceuticals, Inc.

Equities

ELOX

US29014R2022

Delayed OTC Markets
Other stock markets
 12:46:51 2024-04-29 pm EDT 		5-day change 1st Jan Change
0.92 USD +14.17% Intraday chart for Eloxx Pharmaceuticals, Inc. +14.64% -23.33%
Apr. 11 North American Morning Briefing : Stock Futures Edge Lower Ahead of PPI Inflation Gauge DJ
Mar. 13 Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to License ZKN-013 for Rare Dermatological Diseases CI

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to License ZKN-013 for Rare Dermatological Diseases
CI
Almirall Signs License Deal with Eloxx Pharmaceuticals for Skin Diseases Treatment
MT
Eloxx Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Eloxx Pharmaceuticals, Inc. Provides Updates on ELX-02 and ZKN-013
CI
Eloxx Pharmaceuticals, Inc. Reports Drug Response in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome
CI
Eloxx Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Eloxx Pharmaceuticals, Inc. Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis (CF) Patients
CI
Eloxx Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Eloxx Pharmaceuticals Announces FDA Clearance to Begin Single Ascending Dose Study of ZKN-013
CI
Eloxx Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Eloxx Pharmaceuticals Submits Investigational New Drug Application for Treatment of Rare Skin Disease
MT
Eloxx Pharmaceuticals, Inc. Announces Submission of Investigational New Drug Application with U.S. Food and Drug Administration for ZKN-013
CI
Eloxx Pharmaceuticals, Inc. Announces Initiation of Phase 2 Clinical Study Evaluating ELX-02 for the Treatment of Alport Syndrome with First Patient Dosed
CI
Eloxx Pharmaceuticals, Inc. Announces First Patients Enrolled in Phase 2 Clinical Study Evaluating Elx-02 for the Treatment of Alport Syndrome
CI
Reverse Split: 1 of 40
FA
Eloxx Pharmaceuticals Says Board Approves Reverse Stock Split; Shares Drop
MT
Eloxx Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
CI
Eloxx Pharmaceuticals, Inc. Announces Opening of Clinical Trial Sites for Phase 2 Study of ELX-02 for the Treatment of Alport Syndrome
CI
Eloxx Pharmaceuticals' Combo Trial for Cystic Fibrosis Drug Misses Targets
MT
Eloxx Pharmaceuticals, Inc. Announces Topline Results from the Phase 2 Clinical Trial of ELX-02 in Combination with Ivacaftor in Class 1 Cystic Fibrosis (CF) Patients with At Least One Nonsense Mutation
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ELOX Stock
  4. News Eloxx Pharmaceuticals, Inc.
  5. Highlights